Corvidia Therapeutics Closes $60 Million Series B Round Led by Venrock

Equities Research  |

Corvidia Therapeutics, based in Waltham, Massachusetts, announced today that it has closed a $60 million Series B round led by Venrock. Other new investors include Andera (formerly Edmond de Rothschild), Cormorant, HBM Healthcare, Fresenius Medical Care Ventures and Venrock Healthcare Capital Partners. Series A investors Apple Tree Partners, MedImmune, AstraZeneca's global biologics research and development unit, and Sofinnova Partners, Corvidia's founding seed investor, also participated in this round.

We always take notice when Venrock takes interest in a young company. Any readers who may be unfamiliar with Venrock may be familiar with names such as Apple, Intel, Illumina, Checkpoint, Athena Health, Juno and Dollar Shave Club -- all successful Venrock exits.

Corvidia is pioneering the next generation of cardiovascular and cardio-renal therapies, utilizing functional genomics to precisely identify patients with unique sensitivity to specific biologic pathways, allowing for rapid development and an accelerated path-to-market for drugs targeting those pathways. Corvidia is nearing completion of a Phase 2 clinical trial for a genetically-defined patient population living with advanced chronic kidney disease. The company is scientifically focused on cardiovascular indications utilizing the study of genetic variations to ultimately deliver precise treatments to specific patients who have an unmet medical need.

Source: Corvidia Therapeutics

We are extremely pleased to have reached such an important milestone in Corvidia’s advancement as a biotechnology company. This funding is critical to accelerating our clinical programs and adding the necessary scientific and market access infrastructure which will drive our growth in developing precision therapies for patients across a range of complex diseases.

- Marc de Garidel, Chief Executive Officer, Corvidia Therapeutics.

Mr. de Garidel was just named CEO of Corvidia in March 2018. He was previously Chairman and CEO of Ipsen for six years, and previously spent 15 years at Amgen, helping to establish and build significant businesses in nephrology and oncology. He began his career with Eli Lilly.

Corvidia’s innovative approach to cardiovascular drug development allows them to parse complex, heterogeneous conditions and validate disease pathways in patient subpopulations before beginning clinical trials. We have confidence that Corvidia’s highly-respected and experienced team will continue to identify critical therapeutic targets for these devastating diseases through their pioneering approach.

- Karim Helmy, MD, PhD, Vice President, Venrock.


Please email us at content@equities.com to see our Case Studies and Testimonials.

Please click here for information on our new trading platform.

Please click here to see our weekly newsletter.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
INTC Intel Corporation 44.97 -0.92 -2.00 26,639,107 Trade
ATHN athenahealth Inc. 123.85 -1.79 -1.42 253,964 Trade
AAPL Apple Inc. 216.02 -5.17 -2.34 32,637,860 Trade
ILMN Illumina Inc. 321.45 -7.51 -2.28 1,012,103 Trade
LLY Eli Lilly and Company 113.31 -0.28 -0.25 3,619,647 Trade
AMGN Amgen Inc. 202.72 -0.05 -0.02 2,434,002 Trade
AZN Astrazeneca PLC 38.95 -0.34 -0.87 5,898,567 Trade
CELG Celgene Corporation 82.95 -1.33 -1.58 3,250,042 Trade
CHKP Check Point Software Technologies Ltd. 110.78 -1.30 -1.16 1,071,614 Trade
IPSEY Ipsen SA ADR (Sponsored) 36.51 0.24 0.66 3,636

Comments

Emerging Growth

CMX Gold & Silver Corp.

CMX Gold & Silver Corp is an exploration stage company. The Company is engaged in the acquisition, exploration and development of silver and copper/gold properties in the USA.